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1. Introduction 
Since the finding of somatostatin, the hypothala- 
mic inhibitor of pituitary growth hormone, many 
experimental data showing the inhibiting activity of 
somatostatin on the secretion of other hormones 
have been presented [ 11. As for the insulin secretion, 
somatostatin was reported to suppress a glucose- 
induced rise of plasma insulin in humans [2] and to 
inhibit insulin secretion by perfused pancreases 
[2-41. However, concerning its direct effect on in- 
sulin release from the pancreatic islet of Langerhans 
there have so far been two controversial results; 
Although Efendic et al. [3] failed to demonstrate 
the inhibitory effect of somatostatin on insulin 
release from the isolated islet, Oliver and Wagle [5] 
have quite recently reported that the inhibition of 
insulin release from the islet was observed in experi- 
ments with incubation media containing somato- 
statin concentrations ranging from 0.2 to 100 pglml. 
Recently, we have isolated rat pancreatic islets 
under mild conditions of collagenase treatment, and 
studied the effect of somatostatin on glucose-induced 
insulin release by the islet. The purpose of present 
paper is to show that somatostatin, in such a low 
concentration as 10 &ml, did inhibit insulin release 
from the islet and that the somatostatin inhibition of 
insulin release was completely reversed by increasing 
Ca” concentration in the incubation medium. 
2. Methods and materials 
Pancreatic islets of Langerhans were isolated from 
l-2 male Wistar rats weighing 250 g by collagenase 
North-Holland Publishing Company - Amsterdam 
treatment [6] with the following modifications: a) 
the pancreatic pieces were treated in Hanks’ solution 
containing 25 mg collagenase/5 ml and 100 mg bovine 
serum albumin/5 ml; b) the collagenase treatment was 
carried out for 10 min at 37°C using a metabolic 
shaker (approx. 200 oscillations/min). The incubation 
system for insulin release studies was as described pre- 
viously [7,8] with the addition of a protease inhibi- 
tor, Aprotinin (1000 KIU/ml). The islets were preincu- 
bated for 30 min at 37” C in the presence of 3.3 mM 
glucose and then incubated for 90 min at 37°C in the 
presence of 20 mM glucose and various concentrations 
of somatostatin. The insulin content of the incubated 
media was measured by the double antibody redio- 
immunoassay technique [9]. Collagenase (CLS IV, 
Lot No. 44K15 1, 190 U/mg) was purchased from 
Worthington Biochemical Corporation and bovine 
serum albumin (essentially fatty acid free) from Sigma. 
Aprotinin (Antagosan) was a generous gift of Hoechst 
Japan, Ltd. Somatostatin (cyclized) was obtained 
from Bachem Fine Chemicals, Inc., Calif., USA. 
3. Results 
Fig. 1 .shows effective inhibition of glucose-induced 
insulin release from the isolated rat pancreatic islets 
by somatostatin. A continuous increase in insulin 
release in the presence of 20 mM glucose occurred 
during the period of 90 min after incubation (control). 
The increase in insulin release by the islets exposed to 
somatostatin (10 ngjml) was approx. 40% less than the 
comparative increase in the control during the same 90 
min period. 
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Fig. 1. Time course study of insulin release. Incubation medium 
as described in Methods, supplemented with 20 mM glucose 
(0) or 20 mM glucose plus 10 ng/ml somatostatin (0). An 
experiment with low glucose (3.3 mM) was run parallel cm), 
The points at the different time intervals for each curve are 
the mean + S.E. in MU of insulin released in 4 incubation 
flasks. 
Fig.2 shows the results of experiments in which the Curry and Bennett [lo], using perfused rat pan- 
relation between the somatostatin concentration and creases, have reported that increased C$’ concentra- 
the inhibition of glucose-induced insulin release was tion reversed somatostatin inhibition of glucose-induced 
studied. Increasing the concentration of somatostatin insulin secretion. In the present experiments carried 
from 1 to 10 ng/ml decreased the insulin release. out with isolated Langerhans islets of rats, we also 
Little or no further decrease in insulin release was observed reversal of the inhibitory effect of somato- 
caused with somatostatin concentrations up to 1000 statin by increasing the Ca” concentration (table 1). 
ng/ml. In control experiments with low glucose (3.3 When the Ca” concentration in the incubation medium 
mM), it was observed that addition of somatostatin was raised from 5 to 10 mEq/ 1, the inhibitory effect 
(lo- 1000 n$ml) had no significant effect on basal of somatostatin (10 ng/ml) on insulin release was not 
insulin release. significant. 
p=ivs. (0.01 co.01 a01 
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Fig.2. Effect of different concentrations of somatostatin on 
glucose-induced insulin release. Conditions as in fig.1, supple- 
mented with somatostatin at the concentration indicated. 
Results represent the mean + S.E. in rU of insulin released in 
4 incubation flasks. p Values refer to the significance of 
difference of experiments with and without somatostatin. 
Table 1 
Effect of Ca” concentrations on somatostatin inhibition of 
glucose-induced insulin release. 
Ca++ concentration 
5 mEq/l 10 mEq/l 
P P 
Glucose (20 mM) 582 f 39 592 + 40 
Glucose (20 mM) 
+ somatostatin 374 f 19 <O.Ol 552 + 63 N.S. 
(10 ns/ml) 
Conditions as in fig. 1, except that Ca” concentration in the 
incubation medium elevated from its 5 mEq/l control level to 
10 mEq/l. Results are expressed as the mean + S.E. in UU of 
insulin released for 90 min per islet in 4 incubation flasks. p 
Values refer to the significance of difference of experiments 
with and without somatostatin. 
4. Discussion 
In the present study data were presented showing 
that somatostatin has a potent activity of inhibiting 
the glucose-induced insulin release from the isolated 
rat pancreatic islet in a concentration as low as 10 
ng/ml of incubation medium. Further, the somato- 
statin inhibition of insulin release was almost com- 
pletely reversed by increasing Ca” concentration. 
These results strongly suggest hat the hypothalamic 
hormone itself exerts a direct action on insulin release 
from the P-cell of pancreatic islets. 
Additionally, it should be mentioned here that 
while the amount of insulin released by 20 mM glucose 
was 570-600 pU/islet/90 min in the present system, 
that of insulin released by 20 mM glucose from the 
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islets, prepared under the conditions of 60 mg colla- 
genase per 5 ml and a 20 min digestion time, was less 
than 150 pU/islet/90 min. Further, the islets were 
found to be almost insensitive to somatostatin in the 
latter experimental system*. These suggest he pos- 
sible occurrence of damage of some receptor sites for 
glucose as well as for somatostatin on the P-cell mem- 
branes during the course of preparation of islet 
samples. 
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